Intermittent NMDA Antagonist Dosing for Rett Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pervasive developmental disorders, such as Rett Syndrome, do not effectively address the underlying neurological and synaptic abnormalities, leading to persistent symptoms like motor and respiratory dysfunction.
Innovation Solution
Administering a subanesthetic dose of an NMDA receptor antagonist, like ketamine, in an intermittent dosing regimen to alleviate symptoms, combined with a TrkB agonist and agents that modulate BDNF levels, to restore the balance of excitation and inhibition in the brain and improve synaptic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pervasive developmental disorders are used, then symptom management is attempted, but the underlying neurological and synaptic abnormalities are not effectively addressed, leading to persistent symptoms
Solution Approach 1:
The patent uses NMDA receptor antagonists as intermediary substances to modulate neurotransmission and restore E/I balance in the brain. These agents act as mediators between the pathological state and the desired therapeutic state, addressing underlying synaptic abnormalities rather than just managing symptoms.
Solution Approach 2:
The treatment approach changes the physiological parameters of neurotransmission by using subanesthetic doses of NMDA receptor antagonists to shift the excitation-inhibition balance. This parameter change targets the root cause of synaptic dysfunction rather than merely alleviating observable symptoms.
2Reliability
If NMDA receptor antagonists are administered at subanesthetic doses in an intermittent dosing regimen, then forebrain function is improved and abnormal phenotypes are reversed, but the dosing regimen requires careful management to maintain therapeutic effects
Solution Approach 1:
The patent employs periodic (intermittent) administration of NMDA receptor antagonists rather than continuous dosing. This periodic action maintains therapeutic effects while allowing the system to reset, reducing the risk of tolerance development and minimizing side effects.
Solution Approach 2:
The dosing regimen is designed to be dynamic rather than static, adjusting the timing and frequency of administrations based on the intermittent nature of symptom recurrence. This dynamic approach optimizes therapeutic effect while managing treatment complexity.
3Reliability
If subanesthetic dose of NMDA receptor antagonist is administered, then apneic breathing is eliminated and synaptic connectivity is enhanced, but the treatment requires precise dosing to avoid anesthetic effects
Solution Approach 1:
The patent changes the dosage parameter from conventional therapeutic doses to subanesthetic doses of NMDA receptor antagonists. This parameter change achieves therapeutic efficacy through a different mechanism that enhances synaptic connectivity without producing anesthetic effects, though it requires precise dosing control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves forebrain function, reverses abnormal phenotypes, and eliminates apneic breathing in Rett Syndrome models by enhancing synaptic connectivity and structural repair, providing sustained relief from disorder symptoms.
Implementation Method 1
administering a subanesthetic dose of an NMDA receptor antagonist, like ketamine
Implementation Method 2
combined with a TrkB agonist and agents that modulate BDNF levels
Data Source
AI summary
A method of treating a pervasive development disorder in a subject includes administering to the subject a therapeutically effective amount of an NMDAR antagonist, with an intermittent dosing regimen.